Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.46%74.100.0%$2395.49m
NVAXNovavax, Inc. 1.67%170.2999.2%$1218.87m
SRNESorrento Therapeutics, Inc. 5.95%14.421.8%$598.67m
GILDGilead Sciences, Inc. 0.79%69.351.0%$559.14m
AMGNAmgen, Inc. -0.36%240.691.3%$476.61m
REGNRegeneron Pharmaceuticals, Inc. -0.16%620.212.5%$429.51m
BNTXBioNTech SE -0.10%77.000.0%$399.56m
VRTXVertex Pharmaceuticals, Inc. -0.13%272.991.9%$368.45m
BIIBBiogen, Inc. 10.10%305.711.6%$361.06m
ILMNIllumina, Inc. -10.94%355.663.5%$336.82m
VXRTVaxart, Inc. 1.05%9.190.0%$280.99m
EBSEmergent BioSolutions, Inc. 2.91%130.666.4%$180.62m
ALXNAlexion Pharmaceuticals, Inc. -0.60%103.282.0%$166.60m
SGENSeattle Genetics, Inc. -0.83%160.456.0%$163.01m
IBIOiBio, Inc. -6.65%3.790.2%$158.51m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.